Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.53 |
| ▸ | CSF1R | P07333 | 6/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 10/20 | 0.51 |
| ▸ | TYK2 | P29597 | 8/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 5/20 | 0.50 |
| ▸ | JAK3 | P52333 | 4/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608267 | 1.00 | CDK4 (0.53) | CDK4CSF1RCDK6FLT3AXL | |
| SCHEMBL24663774 | 0.93 | AXL (0.60) | CDK4CSF1RCDK6FLT3AXL | |
| SCHEMBL29608968 | 0.93 | AXL (0.60) | CDK4CSF1RCDK6FLT3AXL | |
| SCHEMBL29608022 | 0.88 | AXL (0.58) | CDK4CSF1RCDK6FLT3AXL | |
| SCHEMBL24664549 | 0.88 | AXL (0.58) | CDK4CSF1RCDK6FLT3AXL | |
| SCHEMBL24664431 | 0.86 | FLT3 (0.61) | CDK4CSF1RCDK6FLT3JAK2 | |
| SCHEMBL29608198 | 0.86 | FLT3 (0.61) | CDK4CSF1RCDK6FLT3JAK2 | |
| SCHEMBL24663780 | 0.84 | CDK6 (0.46) | CDK4CSF1RCDK6FLT3JAK2 | |
| SCHEMBL29608252 | 0.84 | CDK6 (0.46) | CDK4CSF1RCDK6FLT3JAK2 | |
| SCHEMBL24663799 | 0.84 | CDK4 (0.51) | CDK4CSF1RCDK6FLT3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423750-B | 2, 4-Disubstituted pyrimidine derivative, preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114423750-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | JAK2, FLT3, JAK1 | CDK4 17/4885CSF1R 91/4885CDK6 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.